...
首页> 外文期刊>Hematology >Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective
【24h】

Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective

机译:以血浆为主要复苏液的最佳创伤复苏:外科医生的观点

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Over the past century, blood banking and transfusion practices have moved from whole blood therapy to components. In trauma patients, the shift to component therapy was achieved without clinically validating which patients needed which blood products. Over the past 4 decades, this lack of clinical validation has led to uncertainty on how to optimally use blood products and has likely resulted in both overuse and underuse in injured patients. However, recent data from both US military operations and civilian trauma centers have shown a survival advantage with a balanced transfusion ratio of RBCs, plasma, and platelets. This has been extended to include the prehospital arena, where thawed plasma, RBCs, and antifibrinolytics are becoming more widely used. The Texas Trauma Institute in Houston has followed this progression by putting RBCs and thawed plasma in the emergency department and liquid plasma and RBCs on helicopters, transfusing platelets earlier, and using thromboelastogram-guided approaches. These changes have not only resulted in improved outcomes, but have also decreased inflammatory complications, operations, and overall use of blood products. In addition, studies have shown that resuscitating with plasma (instead of crystalloid) repairs the “endotheliopathy of trauma,” or the systemic endothelial injury and dysfunction that lead to coagulation disturbances and inflammation. Data from the Trauma Outcomes Group, the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study, and the ongoing Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial represent a decade-long effort to programmatically determine optimal resuscitation practices, balancing risk versus benefits. With injury as the leading cause of death in patients age 1 to 44 years and hemorrhage the leading cause of potentially preventable death in this group, high-quality data must be obtained to provide superior care to the civilian and combat injured.
机译:在过去的一个世纪中,血液储备和输血实践已从全血疗法转向成分疗法。在创伤患者中,无需临床验证哪些患者需要哪种血液制品即可实现向成分治疗的转变。在过去的40年中,这种缺乏临床验证的方式导致了如何最佳使用血液制品的不确定性,并可能导致受伤患者的过度使用和使用不足。但是,来自美国军事行动和平民创伤中心的最新数据显示,在平衡红细胞,血浆和血小板的输血比例的情况下,具有生存优势。这已经扩展到包括院前领域,在该领域中,融化的血浆,RBC和抗纤溶蛋白的使用越来越广泛。休斯敦的德克萨斯创伤研究所遵循了这一进展,将红细胞和解冻的血浆置于急诊室,将液态血浆和红细胞置于直升机上,更早地输注血小板,并使用血栓弹力图指导的方法。这些变化不仅改善了结局,还减少了炎症并发症,手术和血液制品的整体使用。此外,研究表明,用血浆(而非晶体)复苏可修复“创伤性内皮病”或导致凝血功能紊乱和炎症的全身性内皮损伤和功能障碍。创伤结果小组的数据,前瞻性观察性多中心重大创伤输血研究(PROMMTT)和正在进行的实用随机化最佳血小板与血浆比率试验(PROPPR)代表了以编程方式确定最佳复苏实践,平衡风险与收益的十年之功。由于伤害是1至44岁患者的主要死亡原因,而出血是该组潜在可预防死亡的主要原因,必须获得高质量的数据才能为平民提供优质的护理并与受伤作斗争。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号